What is Semaglutide?
Semaglutide is a long-acting glucagon-like peptide-1 () receptor agonist
Semaglutide — long-acting GLP-1 receptor agonist
In short
Long-acting GLP-1 receptor agonist studied in large-scale clinical models of obesity and glucose homeostasis.
Overview
Semaglutide is a long-acting glucagon-like peptide-1 () receptor agonist
Subcutaneous semaglutide mimics native , binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite through hypothalamic pathways. The 7-day half-life allows weekly dosing.
Molecular information
* C18 fatty-acid conjugation + Aib substitutions for DPP-4 resistance and albumin binding
First-order decay curve at 168.0h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
STEP-1 (n=1961) showed 14.9% reduction over 68 weeks at 2.4 mg weekly. Versus placebo (-2.4%) — 12.5 percentage point difference, record for non-bariatric therapy.
Nausea
common·STEP 1
Vomiting
common·STEP 1
Diarrhea
common·STEP 1
Constipation
common·STEP 1
Reduced appetite / early satiety
common
Headache
uncommon
Pancreatitis (rare, requires discontinuation)
rare
7 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
STEP-1
Phase 3 RCT | 2.4 mg/week | 68 weeks | 14.9% body weight reduction (n=1961)
NEJM · 2021
View the studySTEP-2
Phase 3 RCT | 2.4 mg/week | 68 weeks | 9.6% weight loss + HbA1c -1.6% in T2DM
Lancet · 2021
View the studyInformation about Semaglutide is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.